1-[[3-[Bis(methylsulfonyl)amino]-4-fluorophenyl]methyl]-3-[(4-tert-butylphenyl)methyl]thiourea | 401907-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[[3-[Bis(methylsulfonyl)amino]-4-fluorophenyl]methyl]-3-[(4-tert-butylphenyl)methyl]thiourea
• CAS: 401907-70-8
• 化学式: C₂₁H₂₈FN₃O₄S₃
• 分子量: 501.667
• InChiKey: HXUNTDCXTZXYSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-[[3-[Bis(methylsulfonyl)amino]-4-fluorophenyl]methyl]-3-[(4-tert-butylphenyl)methyl]thiourea 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以54%的产率得到N-{5-[3-(4-tert-Butyl-benzyl)-thioureidomethyl]-2-fluoro-phenyl}-methanesulfonamide
  参考文献：
  名称：

  Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects

  摘要：

  A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.024
• 作为产物：
  描述：

  4-氟-3-硝基苯甲醛 在 吡啶 、 sodium tetrahydroborate 、 盐酸羟胺 、 三乙胺 、 三氟乙酸 、 nickel dichloride 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 1-[[3-[Bis(methylsulfonyl)amino]-4-fluorophenyl]methyl]-3-[(4-tert-butylphenyl)methyl]thiourea
  参考文献：
  名称：

  Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects

  摘要：

  A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.024

文献信息

• Novel thiourea derivatives and the pharmaceutical compositions containing the same
  申请人：Suh Ger Young

  公开号：US20080064687A1

  公开（公告）日：2008-03-13

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为vanilloid受体（VR）的调节剂，并包含相应的药物组合物。作为与vanilloid受体活动相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了一种用于预防或治疗这些疾病的药物组合物。
• US8071650B2
  申请人：——

  公开号：US8071650B2

  公开（公告）日：2011-12-06
• Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects
  作者：Young-Ger Suh、Yong-Sil Lee、Kyung-Hoon Min、Ok-Hui Park、Ho-Sun Seung、Hee-Doo Kim、Hyoung-Geun Park、Ji-Yeon Choi、Jeewoo Lee、Sang-Wook Kang、Uh-taek Oh、Jae-yeon Koo、Yung-Hyup Joo、Sun-Young Kim、Jin Kwan Kim、Young-Ho Park

  DOI：10.1016/j.bmcl.2003.09.024

  日期：2003.12

  A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated. (C) 2003 Elsevier Ltd. All rights reserved.